Bibliografia
1. Berk BA, Packer RMA, Law TH, Volk HA. Investigating owner use of dietary supplements in dogs with idiopathic epilepsy. Res Vet. Sci. 2018;119:276-284.
2. Carrasco MC, Vallejo JR, Pardo-de-Santayana M, Peral D, Martín MA, Altimiras J. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother. Res. 2009 Dec;23(12):1795-1796.
3. Eyres L, Eyres MF, Chisholm A, Brown RC. Coconut oil consumption and cardiovascular risk factors in humans. Nutrition reviews. 2016 Apr 1;74(4):267-280.
4. Ferreira A, Rodrigues M, Fortuna A, Falcao A, Alves G. Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: an in vitro evaluation with focus on antiepileptic drugs. Food Res. Int. 2018;103:110-120.
5. Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP, UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia 2017;58(9):1586-1592.
6. Hand M, Thatcher C, Remillard R. Small animal clinical nutrition. 5th ed Novotny. June 2010:1314p.
7. Kaplan JS, Stella N, Catterall WA, Westenbroek RE. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc. Natl. Acad. Sci. USA. 2017;114(42):11229-11234.
8. Kearsley-Fleet L, O’Neill DG, Volk HA, Church DB, Brodbelt DC. Prevalence and risk factors for canine epilepsy of unknown origin in the UK. Vet. Rec. 2013;172:338.
9. Lane SB, Bunch SE. Medical management of recurrent seizures in dogs and cats. J. of Vet. Inter. Med. 1990;4:26-39.
10. Law TH et coll. A randomised trial of a medium-chain TAG diet as treatment for dogs with idiopathic epilepsy. British J. of Nutrition. 2015;114(09):1438-1447.
11. Leuschner J, Müller J, Rudmann M. Characterisation of the central nervous depressant activity of a commercially available valerian root extract. Arzneimittelforschung. 1993 Jun;43(6):638-641.
12. Lujan ASS, Anderson TK. The role of diet in refractory canine epilepsy: a retrospective case series. Abstract of the BSAVA Congress, Quedgeley, UK. Scientific Proceedings 2004:53.
13. Matthews H, Granger N, Wood J, Skelly B. Effects of essential fatty acid supplementation in dogs with idiopathic epilepsy: a clinical trial. Vet. J. 2012;191:396-398.
14. Patterson EE, Muñana KK, Kirk CA, et coll. Results of a ketogenic food trial for dogs with idiopathic epilepsy. J. Vet. Intern. Med. 2005;1:421.
15. Taha AY, Burnham WM, Auvin S. Polyunsaturated fatty acids and epilepsy. Epilepsia, 2010;51:1348-1358.
16. Torres-Hernandez BA, Del Valle-Mojica LM, Ortiz JG. Valerenic acid and Valeriana officinalis extracts delay onset of Pentylenetetrazole (PTZ)- induced seizures in adult Danio rerio (Zebrafish). BMC Complement. Altern. Med. 2015;15:228.
TORNA INDIETROL’interesse dei trigliceridi a catena media nei cani epilettici
Riguardo all’epilessia, diverse pubblicazioni scientifiche menzionano i vantaggi dei trigliceridi a catena media nel controlloclinico, in aggiunta o addirittura in sostituzione dei normali antiepilettici. Questo interesse è in crescita in quanto la terapia abituale è associata a effetti avversi clinicamente significativi come sedazione, polifagia, polidipsia, persino atassia, inoltre biologicamente promuove l’induzione di enzimi epatici che provoca, a lungo termine, l’insorgenza di epatopatie. Un recente studio valuta l’impatto dell’integrazione con trigliceridi a catena media nella gestione dei cani con epilessia e monitora la frequenza e la gravità degli effetti collaterali.
